The management of endometriosis is influenced by numerous factors that extend beyond the biomedical realm. When it comes to issues such as therapeutic wandering, managing individual symptoms, and the influence of resources on access to care, therapeutic support for this chronic condition highlights the variety of factors that affect medical trajectories. It thus reveals the social and systemic dynamics that influence care and clinical possibilities.
In 2025, several studies have shaped the field of infectious diseases. Cefazolin has replaced anti-staphylococcal penicillins for treating Staphylococcus aureus bacteremia, while shorter 7-day courses are sufficient for other bloodstream infections. Treating the male partner in cases of bacterial vaginosis reduces recurrence risk among heterosexual couples. In virology, tecovirimat has proven ineffective against clade 1 monkeypox virus, declared a global health emergency, highlighting the need for new treatments. Finally, respiratory infection prevention is advancing with RSV vaccination for adults over 60 and a new monoclonal antibody against SARS-CoV-2, sipavibart.
Among the many oncology breakthroughs, this article focuses on three significant advances that are particularly relevant to Switzerland: endometrial cancer, which is now better defined by molecular biomarkers, oncogeriatrics, which has become a standard in light of an aging population, and pancreatic cancer, for which solutions have long been lacking, but where early detection tools and new targeted therapies are finally emerging. These are three modern, concrete, and hopeful topics.
The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol-revised) is the gold standard for assessing the severity of alcohol withdrawal. It allows the dosage of benzodiazepines to be adjusted according to symptom intensity rather than prescribing them at a fixed dose, with the aim of limiting prolonged use and the associated risk of dependence. Randomized trials have shown that this approach reduces both the total amount of benzodiazepines administered and the duration of treatment without compromising clinical efficacy or increasing alcohol withdrawal-related complications. However, CIWA-Ar use requires prior training of healthcare providers. Dosage is adjusted according to the score (<8: monitoring; 8-15: standard dose; >15: increased dose). The scale is contraindicated in uncooperative, confused, or intubated patients.
In 2025, several major advances have marked the field of neurology. Anti-FcRN and anti-C5 antibodies have confirmed their long-term efficacy in the treatment of myasthenia gravis. Bruton tyrosine kinase inhibitors have expanded the therapeutic arsenal for multiple sclerosis. An antibody targeting α-synuclein appears to slow motor decline in early-stage Parkinson's disease. The efficacy of late thrombolysis in strokes with radiological mismatch has been confirmed. A blood biomarker facilitates early detection of Alzheimer's disease, and Swiss guidelines specify the modality for the use of anti-amyloid therapies in this disease. Finally, in pregnant women with epilepsy, the recommended dose of folic acid has been reduced.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：